Sign Up Today and Learn More About Nucleix Stock
Invest in or calculate the value of your shares in Nucleix or other pre-IPO companies through EquityZen's platform.
Nucleix Stock (NUCL)
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests.
About Nucleix Stock
Founded
2008
Industries
Manufacturing, Science and Engineering, Health Care
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Nucleix Press Mentions
Stay in the know about the latest news on Nucleix
Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung ...
businesswire • Apr 06, 2024
Liquid Biopsy Technology Industry to Witness Massive Growth ...
artrocker • Dec 26, 2023
Startup Vesica Health to Revive MDxHealth Bladder Cancer ...
precisionmedicineonline • Dec 26, 2023
With 2024 Launch of Multi-Cancer Test, EDGC Plans Entry ...
genomeweb • Dec 26, 2023
Nucleix Receives Reimbursement for Bladder EpiCheck® in the Netherlands
biospace • Nov 08, 2023
Nucleix Management
Leadership team at Nucleix
Co-founder, VP Software & Analytics
Adam Wasserstrom
VP Research & Co-founder
Danny Frumkin
Join now and verify your accreditation status to gain access to:
- Nucleix current valuation
- Nucleix stock price
- Available deals in Nucleix and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Nucleix Stock
How to invest in Nucleix stock?
Accredited investors can buy pre-IPO stock in companies like Nucleix through EquityZen funds. These investments are made available by existing Nucleix shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Nucleix stock?
Shareholders can sell their Nucleix stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
